Claims:

1. A non-naturally occurring and/or purified and/or engineered T cell receptor (TCR) having the property of binding to FMNKFIYEI (SEQ ID No: 1) HLA-A2 complex and comprising at least one TCR alpha chain variable domain and/or at least one TCR beta chain variable domain,

the alpha chain variable domain comprising an amino acid sequence that has at least 90% identity to the sequence of amino acid residues 1- 112 of SEQ ID No: 2, and

the beta chain variable domain comprising an amino acid sequence that has at least 90% identity to the sequence of amino acid residues 1- 112 of SEQ ID No: 3,

wherein the alpha chain variable domain includes a mutation in one or more of the amino acids corresponding to 31Q, 32S, 94D, 95S, 96G, 97Y and 98A.

2. The TCR of claim 1, wherein the alpha chain variable domain includes at least one of the following mutations:

Residue no.		
31Q	F	Y
32S	A	
94D	Q	
95S	N	
96G	S	
97Y	V	
98A	S	

3. The TCR of any preceding claim, wherein the alpha chain variable domain comprises an amino acid sequence having at least 90% identity to residues 1- 112 of any one of SEQ ID No: 6, SEQ ID No: 7, SEQ ID No: 8, SEQ ID No: 9, SEQ ID No: 10, SEQ ID No: 11, SEQ ID No: 12, SEQ ID No: 13, SEQ ID No: 14, SEQ ID No: 15, SEQ ID No: 16, SEQ ID No: 17, SEQ ID No: 18, SEQ ID No: 19 and SEQ ID No: 20.

4. The TCR of any preceding claim, wherein the alpha chain variable domain comprises Q1 to H112 of SEQ ID No: 11, SEQ ID No 12 or SEQ ID No 13 and/or the beta chain variable domain comprise D1 to T112 of SEQ ID No: 3.

5. The TCR of any preceding claim having an alpha chain TRAC constant domain sequence and/or a beta chain TRBC1 or TRBC2 constant domain sequence.

6. The TCR of claim 5, wherein, the alpha and/or beta chain constant domain sequence(s) are modified by truncation or substitution to delete the native disulfide bond between Cys4 of exon 2 of TRAC and Cys2 of exon 2 of TRBC1 or TRBC2.

7. The TCR of claim 5 or claim 6, wherein the alpha and/or beta chain constant domain sequence(s) are modified by substitution of cysteine residues for Thr 48 of TRAC and Ser 57 of

TRBC1 or TRBC2, the cysteines forming a disulfide bond between the alpha and beta constant domains of the TCR.

8. The TCR of any preceding claim, which is in single chain format of the type Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ, Vα-L-Vβ-Cβ, or Vα-Cα-L-Vβ-Cβ wherein Vα and Vβ are TCR α and β variable regions respectively, Cα and Cβ are TCR α and β constant regions respectively, and L is a linker sequence.

9. The TCR of any one of claims 1-7, which is an alpha-beta heterodimer.

10. The TCR of any preceding claim associated with a detectable label, a therapeutic agent or a PK modifying moiety.

11. Non-naturally occurring and/or purified and/or engineered nucleic acid encoding the TCR of any one of the preceding claims.

12. A non-naturally occurring and/or purified and/or engineered cell, especially a T-cell, presenting a TCR as claimed in any one of claims 1-10.

13. A cell harbouring

(a) a TCR expression vector which comprises nucleic acid as claimed in claim 11 encoding in a single open reading frame, or two distinct open reading frames, the alpha chain and the beta chain respectively; or

(b) a first expression vector which comprises nucleic acid encoding the alpha chain of a TCR as claimed in any of claims 1 to 10, and a second expression vector which comprises nucleic acid encoding the beta chain of a TCR as claimed in any of claims 1 to 10.

14. A pharmaceutical composition comprising a TCR as claimed in any one of claims 1 to 10 or a cell as claimed in claim 12 or claim 13, together with one or more pharmaceutically acceptable carriers or excipients.

15. A TCR as claimed in any one of claims 1 to 10 , or a cell as claimed in claim 12 or claim 13, for use in medicine.

16. The TCR or cell for use of claim 15, for use in a method of treating cancer.

17. The TCR or cell for use of claim 16, wherein the method comprises adoptive therapy.